Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapy.

<h4>Background</h4>Current evidence on circulating tumor DNA (ctDNA) in the adjuvant setting of early breast cancer (eBC) confirms its high prognostic value. CtDNA-positive patients without radiographic signs of relapse show reduced disease-free and overall survival. Secondary adjuvant treatment int...

Descrición completa

Detalles Bibliográficos

Principais autores:	Kerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, Franziska Mergel, Sophia Huesmann, Forca Mehmeti, Henning Schäffler, Angelina Fink, Tatjana Braun, Sabine Heublein, Lisa Wiesmüller, Klaus Pantel, Brigitte Rack, Peter A Fasching, Wolfgang Janni
Formato:	Artigo
Idioma:	Inglês
Publicado:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Acceso en liña:	https://doi.org/10.1371/journal.pone.0322156
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!